← All trials
NCT03962296
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 21, 2012
- Primary completion
- Jan 26, 2015
- Completion date
- Jan 26, 2015
- First posted
- —
- Last posted
- —
- Enrollment
- 153
- Arms / groups
- 3 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Hanyang UniversityLead sponsor
- Hanlim Pharm. Co., Ltd.Collaborator
- Hanyang UniversityReponsible party - principal investigator
- Hallym UniversityOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.